Nektar Therapeutics (NASDAQ:NKTR) announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of NKTR-181, a first-in-class, opioid analgesic molecule with …
Roth Capital analyst Debjit Chattopadhyay weighed in on Nektar Therapeutics (NASDAQ:NKTR), as the company will announce its financial results for the fourth-quarter on February 24, 2015. The …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a …
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a$21 price target, following the news that NKTR’s partner Baxter International …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price …
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a price target …
In a research report released today, analyst Debjit Chattopadhyay of Roth Capital maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price target, which …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price …
